TriMas Q3 net sales rise 7.7% to $178.7 million; operating profit $11.5 million
TriMas reported third-quarter 2026 net sales of $178.7 million, up 7.7% from a year earlier, and GAAP income from continuing operations of $13.5 million, compared with a loss in the prior-year quarter. The company reaffirmed its full-year 2026 adjusted EPS outlook of $1.60 to $1.70 and raised its sales growth outlook to 4% to 6%, while Specialty Products' operating margin declined and it agreed to sell the Rapak business.
Key points
- Net sales were $178.7 million, up 7.7% from $166.0 million; GAAP diluted EPS from continuing operations was $0.37, compared with a loss of $0.12.
- Adjusted diluted EPS from continuing operations was $0.50, up from $0.17, which the company attributed mainly to interest income, cost reductions and a lower share count.
- 2026 adjusted diluted EPS outlook was reaffirmed at $1.60 to $1.70; the sales growth outlook was raised to 4% to 6% from 3% to 6%.
- Repurchased 233,150 shares for $9.3 million in the third quarter; $67.3 million remains under the authorization. Cash and cash equivalents were $1,158.5 million at September 30, 2026.
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.